Merck KGaA makes noise in hematology with $1.1B Silence buy
Merck KGaA makes noise in hematology with $1.1B Silence buy
Merck KGaA
Profile of Merck KGaA created from news harvest. To be enriched by user.
Company Info
Sector:Science & Technology / Healthcare (E.Merck)
Headquarters:Darmstadt, Germany
Founded:1668
Website:www.emdgroup.com/en
Clinical Development Pipeline
Undisclosed
Target: TBDWorkforce & Restructuring Tracker
View Industry Layoff Tracker →Up to 70 US R&D rolesPlanned / Reported
Merck KGaA instituted a strict in-office requirement and R&D restructuring across its U.S. research hub in Massachusetts that is projected to result in up to 70 layoffs.
Recent News
Merck KGaA buys Silence in $1.3B deal for blood cancer drug
Germany's Merck KGaA has picked up Silence Therapeutics to the tune of $1.3 billion in the wake of the British biotech's mid-stage success for its challenger to Takeda's Mimrylo.
New Merck KGaA in-office requirement could lead to 70 US layoffs
New Merck KGaA in-office requirement could lead to 70 US layoffs
Merck KGaA pledges $50M to new biotech with eye to acquisition
Merck KGaA committed $50M to launch a new cardiovascular biotech, with plans to acquire the company once its pipeline matures.
Leadership Team
Kai Beckmann
Chief Executive Officer (effective May 2026)